Investors

Corporate Governance

Chair’s Introduction

Incanthera’s Board and management team possess a broad range of commercial, scientific and public company experience.

The Board comprises individuals who have all held long and distinguished position within the healthcare industry.

Our CEO, Dr Simon Ward’s scientific and educational background, along with commercial experience provides the perfect platform to oversee his vision to transform the method and quality of technologies from laboratory to patient, that is the heart of Incanthera’s business.

My own experience in over 35 years of healthcare and corporate roles combined, has provided the opportunity of Chairmanships and team building, alongside all aspects of commercial and industry activity, and I am delighted to be part of the team here at Incanthera.

We are fortunate to have had the long term support of Dr Alan Warrander, as Independent Non-Executive Director, whose large Pharma and cross- section of company experience, provides an invaluable sounding board of perception and wise counsel.

Our Key Senior Management team is diverse and skilled, providing every aspect we require to not only progress, but flourish. Their individual qualities have shown resilience, determination and the experience to fulfil our ambitions.

Pawel Zolnierczyk, our COO, provides exceptional management of our IP and commercial partnership activities and overseeing of our portfolio.

Laura Brogden, CFO, ensures our financial, compliance, shareholder information and company secretarial obligations are fulfilled and met with ample time and poise. Suzanne Brocks, Head of Communications, oversees City, company and public facing communications, ensuring both internally, and to the public, that we are delivering our message and maximising our opportunities.

These full spectrum qualities, ensure industry and commercial ambitions are met and opportunities and evolution are at the forefront of our strategic drive year after year and I can say with confidence that the team at Incanthera is the right one to deliver our own growth and commercialisation goals into future rewards to shareholders.

Tim McCarthy
Executive Chairman

Tim has more than 35 years’ international senior level business experience in the Healthcare, Biotech and Technology sectors.

He is also the Non-Executive Chairman of ImmuPharma plc, an AIM quoted specialist drug discovery and development company and of 4basebio UK Societas, an AIM quoted company developing next generation gene therapy technologies and solutions.

Tim is a former CEO and Finance Director of a number of public and private companies, including Alizyme plc and Peptide Therapeutics Group plc. He has also co-founded a number of healthcare and biotechnology companies. A Fellow of the Association of Chartered Certified Accountants, he also has an MBA from Cranfield School of Management.

Dr Simon Ward
Chief Executive Officer

Simon is a co-founder of Incanthera and has more than 30 years’ senior experience in academia and business.

He was a founder and CEO of Molecular SkinCare Limited, a pioneer and developer of novel dermatology products for the prevention and management of skin diseases. As CSO of York Pharma plc, he was responsible for bringing innovative dermatology product through to market. Simon also served as chairman of South Yorkshire Bioscience Enterprise Network (SYBEN) and deputy chairman of Medipex, a healthcare innovation hub for NHS organisations across industry and academia internationally.

Simon graduated from the University of London’s School of Pharmacy (UK) with a Joint Honours Degree in Pharmacology and Toxicology and was awarded a DPhil in the Department of Human Anatomy, Oxford University under a Glaxo Group Research Studentship.

Dr Alan Warrander
Independent Non-Executive Director
Remuneration Committee Chair

Alan is an expert in partnering and licensing with significant experience of global pharma drug discovery and drug development processes having more than 30 years’ experience in the Pharmaceutical Industry, including 21 years with AstraZeneca, holding many positions including Director of Global Licensing.

He has a BSc in Chemistry and Biochemistry and a PhD in Biochemistry.

For the lead development programme, Sol, the Company is working closely with two key individuals:

Professor Adrian Davis

Professor Davis is a physical pharmaceutical chemist, who joined Glaxo Smith Kline (GSK) as a skincare formulation specialist in 1971, retiring in 2004 as Director of Dermatological New Product Research. He provides expert advice on skincare product formulation. He is an adviser to many of the world’s leading Pharma companies. Professor Davis is the author of over 20 patents, the majority of which are in the area of dermatological drug delivery, his specialist area for the last twenty years. He has published both original research and review chapters in the area of dermatological drug delivery and is a reviewer for several international journals. His particular interest is in rational drug dosage and drug delivery to optimise therapeutic potential. Professor Davis lectures internationally and is an honorary Professor at the UCL School of Pharmacy, London. He is a founder member and past Chairman of Skin Forum, a multidisciplinary group whose aim is to promote dermatological research and improve patient therapy.

Dr Kevin Hammond

Dr Hammond has over 30 years’ experience working with some of the world’s leading Pharmaceutical, FMCG and Healthcare companies, where he has held responsibilities in directing new product innovation, partnering, licensing, and technology acquisition, for companies such as Reckitt Benckiser, Unilever, PZ Cussons, CB Fleet (US) and GSK. His experience includes operations in Europe, Latin America, North America, South East and Central Asia.

In 2010, Dr Hammond set up his own consultancy aimed at advising and working with SMEs and University spin-out companies seeking to commercialise their technologies in the Pharmaceutical, Healthcare and FMCG markets. Since this time, he has secured significant returns for clients through facilitating ‘entry’ into potential customer companies, partnering contracts, technology sales, and licensing and royalty agreements, including deals with companies such as P&G, GSK and Coty.